{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:20:07Z","timestamp":1784679607389,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ijgc.2025.101927","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:12:22Z","timestamp":1747163542000},"page":"101927","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Unnecessary exclusions: eligibility criteria in gynecologic oncology interventional clinical trials impairs access"],"prefix":"10.1016","volume":"36","author":[{"given":"Sharonne","family":"Holtzman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riva","family":"Letchinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel S.","family":"Chess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9196-5408","authenticated-orcid":false,"given":"Daniel","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunidhi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0094-0161","authenticated-orcid":false,"given":"Dmitry","family":"Zamarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstatin","family":"Zakashansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie V.","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijgc.2025.101927_bib1","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ygyno.2023.05.006","article-title":"Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: a joint statement from GOG foundation and Society of Gynecologic Oncology (SGO)","volume":"174","author":"Pothuri","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"33","key":"10.1016\/j.ijgc.2025.101927_bib2","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","article-title":"Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement","volume":"35","author":"Kim","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2025.101927_bib3","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1158\/1078-0432.CCR-20-3852","article-title":"Continuing to broaden eligibility criteria to make clinical trials more representative and inclusive: ASCO-friends of cancer research joint research statement","volume":"27","author":"Kim","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.ijgc.2025.101927_bib4","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials: race-, sex-, and age-based disparities","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ijgc.2025.101927_bib5","unstructured":"National Cancer Institute Clinical Trials and Translational Research Advisory Committee (CTAC) strategic Planning Working Group. Novermber. 4; 2020. Accessed 2\/1\/24. https:\/\/www.cancer.gov\/about-nci\/advisory-boards\/ctac."},{"issue":"16","key":"10.1016\/j.ijgc.2025.101927_bib6","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1056\/NEJMp1615879","article-title":"Reevaluating eligibility criteria - balancing patient protection and participation in oncology trials","volume":"376","author":"Beaver","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ijgc.2025.101927_bib7","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1681\/ASN.2014101034","article-title":"Cause-specific deaths in non-dialysis-dependent CKD","volume":"26","author":"Navaneethan","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101927_bib8","doi-asserted-by":"crossref","first-page":"992","DOI":"10.2215\/CJN.00090108","article-title":"Higher serum creatinine concentrations in black patients with chronic kidney disease: beyond nutritional status and body composition","volume":"3","author":"Hsu","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.ijgc.2025.101927_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081355","article-title":"Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada","volume":"8","author":"Samji","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ijgc.2025.101927_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129550","article-title":"Cancer-related causes of death among HIV-infected patients in France in 2010: evolution since 2000","volume":"10","author":"Vandenhende","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ijgc.2025.101927_bib11","unstructured":"What is the impact of HIV on racial and ethnic minorities in the U.S.? HIV.gov. Accessed 2\/4\/24. https:\/\/www.hiv.gov\/hiv-basics\/overview\/data-and-trends\/statistics."},{"issue":"9","key":"10.1016\/j.ijgc.2025.101927_bib12","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1002\/cncr.32755","article-title":"Bias and stereotyping among research and clinical professionals: perspectives on minority recruitment for oncology clinical trials","volume":"126","author":"Niranjan","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ijgc.2025.101927_bib13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jpsychires.2015.08.005","article-title":"The exclusion of people with psychiatric disorders from medical research","volume":"70","author":"Humphreys","year":"2015","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.ijgc.2025.101927_bib14","unstructured":"Mental health by the numbers. National Alliance on Mental Illness. Accessed 2\/4\/24. https:\/\/www.nami.org\/about-mental-illness\/mental-health-by-the-numbers\/."},{"issue":"11","key":"10.1016\/j.ijgc.2025.101927_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236525","article-title":"Long-term outcomes of psychological interventions on children and young people\u2019s mental health: a systematic review and meta-analysis","volume":"15","author":"Pilling","year":"2020","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101927_bib16","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/JCO.22.01424","article-title":"Racial and ethnic disparities in cervical cancer incidence, survival, and mortality by histologic subtype","volume":"41","author":"Cohen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101927_bib17","doi-asserted-by":"crossref","first-page":"73.e1","DOI":"10.1016\/j.ajog.2023.09.019","article-title":"Demographic reporting and language exclusion in gynecologic oncology clinical trials","volume":"230","author":"Lee","year":"2024","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101927_bib18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.6004\/jnccn.2022.7068","article-title":"Participation of patients with limited English proficiency in gynecologic oncology clinical trials","volume":"21","author":"Jorge","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"10.1016\/j.ijgc.2025.101927_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003758","article-title":"Evaluating the frequency of English language requirements in clinical trial eligibility criteria: a systematic analysis using ClinicalTrials.gov","volume":"18","author":"Muthukumar","year":"2021","journal-title":"PLoS Med"},{"issue":"6","key":"10.1016\/j.ijgc.2025.101927_bib20","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1177\/1740774515592881","article-title":"Characteristics of clinical trials that require participants to be fluent in English","volume":"12","author":"Egleston","year":"2015","journal-title":"Clin Trials"},{"issue":"14","key":"10.1016\/j.ijgc.2025.101927_bib21","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1056\/NEJMp2215609","article-title":"Why diverse clinical trial participation matters","volume":"388","author":"Schwartz","year":"2023","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1016\/j.ijgc.2025.101927_bib22","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2020.01.040","article-title":"Are ethnic and racial minority women less likely to participate in clinical trials?","volume":"157","author":"Patel","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101927_bib24","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ygyno.2020.03.002","article-title":"Minority participation in phase 1 gynecologic oncology clinical trials: three decades of inequity","volume":"157","author":"Awad","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101927_bib23","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ygyno.2015.05.014","article-title":"Minority participation in Gynecologic Oncology Group (GOG) Studies","volume":"138","author":"Scalici","year":"2015","journal-title":"Gynecol Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25010473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25010473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T13:30:02Z","timestamp":1776346202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25010473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1048891X25010473"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101927","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unnecessary exclusions: eligibility criteria in gynecologic oncology interventional clinical trials impairs access","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101927","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101927"}}